Table 1: Patient characteristics.
| Characteristic | Patients (n = 64) |
| Age (years), median (range) | 59.5 (30-82) |
| Gender, n (%) | |
| Male | 0 (0.0) |
| Female | 64 (100.0) |
| Clinical stage, n (%) | |
| I | 7 (10.9) |
| II | 27 (42.2) |
| III | 24 (37.5) |
| IV | 6 (9.4) |
| Therapeutic response, n (%) | |
| CR | 27 (42.2) |
| PR | 8 (12.5) |
| SD | 17 (26.6) |
| PD | 12 (18.7) |
| DM, n (%) | |
| Present | 30 (46.9) |
| Absent | 34 (53.1) |
| Tissue HER2 status, n (%) | |
| Positive | 64 (100.0) |
| Negative | 0 (0.0) |
| Serum HER2 status, n (%) | |
| Positive | 19 (29.7) |
| Negative | 45 (70.3) |
| Trastuzumab administration, n (%) | |
| Yes | 64 (100.0) |
| No | 0 (0.0) |
CR: Complete Response; DM: Distant Metastasis; HER2: Human Epidermal Growth Factor Receptor type 2; PD: Progressive Disease; PR: Partial Response; SD: Stable Disease.